Treatment Approaches in Metastatic NPC: First-Line Toripalimab + Gemcitabine/Cisplatin
A panelist discusses how toripalimab has emerged as the preferred treatment regimen for metastatic nasopharyngeal carcinoma (NPC), according to NCCN guidelines, based on improved survival outcomes in clinical trials compared with traditional chemotherapy approaches alone, though individual patient factors including performance status, prior treatments, and specific tumor characteristics must be carefully considered when personalizing the treatment strategy.
Video content above is prompted by the following:
- Please discuss your clinical experience with treatment strategies for metastatic NPC.
- Given the NCCN guidelines, indicating toripalimab as the preferred regimen, what are your thoughts on the treatment approach for this patient?
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
